Could Gut Modulation through Probiotic Supplementation Be Beneficial in Autism Spectrum Disorder? by El Khatib, Rouba et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
1Chapter
Could Gut Modulation through 
Probiotic Supplementation Be 
Beneficial in Autism Spectrum 
Disorder?
Rouba El Khatib, Dolla Karam-Sarkis,  
Anne-Judith Waligora-Dupriet and Marie-José Butel
Abstract
Evidence is mounting to a possible link between autism spectrum disorder 
(ASD) and gut microbiota through the well-known gut-brain axis. Numerous 
mechanisms have been suggested including bacterial metabolites that could involve 
in chemokines, antimicrobial peptides, or neuropeptides production. Hence, 
numerous studies reported dysbiosis in autistic patients. Antibiotic courses are 
known to more or less improve neurobehavioral symptoms; however, it could lead 
to side effects. Modulation of the gut microbiota using pro- and/or prebiotics is 
therefore an appealing way of treatment. Fecal microbiota transfer is suggested to 
be an alternative new approach that could be promising. The aim of our chapter 
will be first to briefly review the current data concerning the possible role of the 
gut microbiota and its mechanisms in ASD and second to review the interest and 
limits of the pre- and probiotic supplementations in ASD treatment. Lastly, we will 
discuss on the potential interest of the microbiota transfer in ASD.
Keywords: autism spectrum disorder, gut microbiota, dysbiosis, probiotics, 
prebiotics, fecal microbiota transplantation
1. The human microbiota
1.1 Definition and functions
The term microbiota describes the entirety of all bacterial, viral, fungal, 
protozoal, and archaeal microorganisms living on almost every cutaneous and 
mucosal surface of the body [1]. The gut microbiota (GM) inhabited by several 
trillion microorganisms that live in a symbiotic relationship with the host repre-
sents the most heavily colonized area of the human body. It is mainly dominated 
by organisms belonging to four major phyla that together account for more than 
90% of the total bacterial population: Bacteroidetes, Firmicutes, Proteobacteria, and 
Actinobacteria, followed by the minor phyla Fusobacteria and Verrucomicrobia. 
With a number of microorganisms being around 10 times higher than the number 
of human cells and a number of genes nearly 150 times greater than the human 
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genome, the GM is now recognized as an environmental factor that affects normal 
host physiology, metabolism, immunity, brain function, and behavior.
During recent decades, the development of high-throughput sequencing 
technology has hugely contributed to increased understanding of host-microbe 
interactions in health and disease [2]. First, GM offers a barrier, protecting against 
external factors and proliferation of pathogenic microbes, through various mecha-
nisms such as increasing mucus production, reinforcing intestinal epithelium 
permeability, and production of bacteriocins and antimicrobial peptides. GM is also 
involved in many fundamental metabolic functions such as synthesis of essential 
nutrients, hormones, vitamins, supply of energy from dietary sources otherwise 
unavailable to host and clearance of drugs, and toxins. Furthermore, GM is shown 
to be involved in the maturation of the host immune system, where specific strains 
such as Bifidobacterium and Lactobacillus produce anti-inflammatory cytokines, and 
others such as Clostridium and Ruminococcus produce pro-inflammatory cytokines. 
Hence, GM is essential for the development of innate and acquired immunity 
through stimulation of local and systemic immune responses.
Lastly, very recently there is mounting evidence of the significant influence of 
GM in the modulation of brain activity and behavior across the so-called “microbi-
ota-gut-brain axis (GBA)” [3]. The GBA consists of bidirectional communication 
between the central nervous system (CNS), the enteric nervous system, and the gut 
linking emotional and cognitive centers of the brain with peripheral intestinal func-
tions [4]. The exact mechanisms of signal transmission within this network are not 
completely elucidated. The CNS asserts its role over the GM through influencing 
gut motility patterns, altering the equilibrium in the gut permeability, and modulat-
ing mucus secretion which are known to exert control over gut microbial composi-
tion [5]. Conversely, the GM claims its influence over the CNS by regulating the 
hypothalamic-pituitary-adrenal axis and the production and turnover of cytokines 
and neurotransmitters. In addition to their effects on development and maturation 
of the enteric nervous system, these neuroactive metabolites can signal beyond the 
local gastrointestinal (GI) tract to the distant CNS potentially through signaling 
pathways that include the vagus nerve. Catecholamines can modulate important 
processes, including neurogenesis, myelination, microglia activation, brain plastic-
ity, and blood-brain barrier permeability [6]. Indeed, recent studies demonstrated 
that, under extreme conditions (e.g., in a germ-free environment or during anti-
biotic (ATB) treatment), GM absence is associated with several abnormalities in 
brain gene expression and neurophysiology [7]. Interestingly, these aberrations are 
reversed after colonization with a conventional GM [8] or even specific bacterial 
species [7]. Thus, the disruption of neural, endocrine, immune, and metabolic 
mechanisms that are involved in gut-CNS signaling seems to be involved in neuro-
psychiatric, neurobehavioral, neurodegenerative, and mental disorders.
1.2 Colonization of intestinal ecosystem in early life and its evolution
The composition of the GM varies widely from fetal life to adult age. Until 
recently, babies were believed to be born sterile and only populated by microbes on 
exposure to their first postdelivery environments. Recent research suggests that the 
process of microbial colonization of the GI tract could begin prenatally as acquisi-
tion of maternal microbiota might occur during intrauterine life via placenta [9]. 
However, these findings are questionable, and recent data strongly suggest that 
bacteria isolated in utero are rather a contamination linked to the sampling methods 
than a specific microbiota [10]. Neonates show unstable and highly dynamic intes-
tinal microbiota with a low microbial diversity. First colonizers in healthy neonates 
are enterobacteria, Staphylococcus, and Streptococcus, followed by strict anaerobes 
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such as Bacteroides, Bifidobacterium, and Clostridium [11]. This pattern of microbial 
diversity provides an efficient means for adaptation to the variable circumstances 
over a lifetime such as changes in lifestyle, illness, puberty, and others. Over the 
first few years of life, GM matures and stabilizes to a more balanced “adult-like” 
composition at around the end of the third year [12].
Interestingly, the brain of neonates grows to approximately 90% of its future adult 
volume until the age of two, and the formation of new synapses in the brain peaks dur-
ing this period [13]. Thus, the critical window for establishment of a healthy microbial 
composition falls into the same critical time window for brain development. Therefore, 
understanding GM establishment and its critical developmental window in early child-
hood is important because any perturbation during this period causes long-lasting 
effects on the development of the CNS. Being more flexible at infantile in contrast to 
the subsequent life, this temporal requirement may have important ramifications for 
potential preventative and therapeutic remediation strategies.
2. Autism spectrum disorder and the gut microbiota
2.1 Gut microbiota involved in the pathogenesis of autism spectrum disorders
Microbiota role in health and disease is as crucial as is complex. Alterations in 
normal commensal GM (known as dysbiosis) have been widely reported as a key 
contributor to the etiology and/or pathogenesis of various diseases including several 
neurobehavioral conditions, such as Parkinson’s disease, schizophrenia, Alzheimer’s 
disease, depression, anxiety, and most compellingly autism spectrum disorder 
(ASD) [14].
ASD refers to a group of heterogeneous and complex neurodevelopmental dis-
orders characterized by impaired social interactions and reciprocal communication 
skills as well as restricted, repetitive, and stereotyped patterns of behavior, inter-
ests, and activities [15]. Over the last decades, a steady increase of ASD prevalence 
has been reported worldwide. ASD is currently estimated to affect about 1 in every 
68 children, with greater incidence found among boys (4:1) [14]. To date, the etiol-
ogy of ASD remains elusive, and it is thought to involve both genetic predisposition 
and different environmental triggers. Although several genetic factors are known 
to influence the etiology of different types of ASD, these only apply to a minor part 
of the autistic population. By estimate, the heritability accounts approximately 
for only 35–40% of the contributing elements and the remaining 60–65% results 
from the combination of prenatal, perinatal, and postnatal environmental factors 
as well as related medical disorders [16]. Besides, along with significant psychiatric 
symptoms, ASD is often characterized by a number of medical comorbidities, the 
most prominent of which implicates the GI tract. Children with ASD experience 
significantly more GI symptoms than children without ASD occurring nearly at 
a fourfold greater rate [17]. Symptoms include constipation, diarrhea, abdomi-
nal pain, bloating, gastroesophageal reflux, and food selectivity and seem to be 
strongly associated with the severity of ASD behaviors. Clinical abnormalities such 
as altered GI motility and increased gut permeability have also been reported [18]. 
The cause of ASD-associated GI problems is difficult to ascertain, but it appears to 
partly relate to the excessive use of oral ATBs which can alter GM. Indeed, several 
studies report increased use of oral ATBs in children with ASD compared to neu-
rotypical children. By eliminating beneficial indigenous GM, long-term ATB use 
destabilizes microbial community and creates favorable environment for coloniza-
tion by potentially harmful (toxin-producing) microorganisms. Thus, considering 
the potential interactions between intestinal microbes and the CNS, loss of the 
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protective commensal microbiota along with the overgrowth of pathogenic micro-
organisms is hypothesized to cause or contribute not only to GI dysfunction but also 
to ASD-related behavioral symptoms. All these findings have gained an insight into 
the influence of GM in ASD as potential mediator of risk factors.
2.2 Disruptions of microbial colonization in autism spectrum disorder
Imbalances in GM composition at the first stages of life and concomitant behav-
ioral changes have been related to various prenatal and early-life events [8].
Mode of birth, whether through natural birthing process or Cesarean section 
(C-section), greatly affects the initial microbial settlement. Vaginally delivered 
babies harbor bacteria similar to their mothers’ fecal and vaginal microbiota with 
dominance of Bifidobacterium, whereas babies born via C-section would acquire 
an altered GM composition resembling to their mother’s skin microbiota as well as 
microbes from the surrounding environment with a delayed colonization by bac-
teria from maternal origin, mainly enterobacteria, bifidobacteria, and Bacteroides 
[11]. Interestingly, these modifications can persist for several months [2]. Thus, 
concern has arisen that this reduced microbial diversity and altered bacterial profile 
in babies delivered via C-section could contribute to ASD. Indeed, studies employ-
ing animal models have revealed that, compared with vaginally delivered animals, 
those delivered by C-section suffer more frequently from behavioral abnormalities 
that have been associated with ASD [19]. Consistent with this, some clinical studies 
report that C-section births in comparison to natural vaginal delivery are associated 
with a significantly 23% higher risk of the child developing ASD [20]. Thus, the 
importance of C-section in conditioning negative effects on the CNS is debated.
In terms of gestational age at birth, preterm neonates (PT) are characterized 
by a delayed microbial colonization, missed or reduced acquisition of Lactobacillus 
and Bifidobacterium, greater abundance of Proteobacteria, and earlier acquisition 
of Firmicutes [11], hence increasing the risk to develop later disease. One study 
reported a relationship between premature birth and an increase risk of ASD 
development [21]. Interestingly, each week of shorter gestation was associated with 
an increased risk of ASD. The early development of infant at birth has also been 
recognized as a biomarker of future risk of neurodevelopmental disorders. Besides, 
gestational growth affects the neurodevelopment, and both infants born small or 
large for gestational age are associated with higher rates of ASD [22].
Early feeding pattern also interferes greatly in the regulation of the intestinal 
colonization, with breastfed infants harboring a less diverse but more stable and 
uniform GM. Specific biological markers of healthy GM, including early coloni-
zation of Bifidobacterium and greater prevalence of Lactobacillus, characterize 
microbial communities of breastfed infants [11]. By contrast, increased species 
richness accompanied by an overrepresentation of Clostridium prevails in bottle-
fed ones. In fact, cognitive functioning and neurological development of children 
have been associated with the duration of exclusive breast-feeding and introduc-
tion of formula feed [23]. Remarkably, breast-feeding appears to be less frequent 
and, when present, occurs for a much shorter duration in children with ASD [24]. 
Further differentiation occurs after the introduction of solid foods. Feeding pat-
terns and strong food preferences of ASD children for nutrient-poor starchy foods 
while rejecting fruits, vegetables, and proteins may lay the foundation of an abnor-
mal GM. The high prevalence of ASD in some countries has been correlated with 
typical carbohydrate rich diet and consequently predominance of genera Prevotella 
and Megasphaera [25]. Therefore, understanding how these changes affect human 
GM suggests that early dietary habits have a more complex effect on the metabolic 
programming of a child than previously anticipated.
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Additional modifications are induced by exposure to drugs either directly or 
indirectly from the mother. ATB-induced shifts in the gut microbial composition 
can persist several months after cessation of the treatment, inducing long-term 
dysbiosis [26]. An association between long-term ATB use, hospitalization, abdomi-
nal discomfort, and the onset of ASD symptoms has been shown [27]. Likewise, a 
population-based cohort study revealed the use of various ATBs during pregnancy 
as a potential risk factor for ASD [28]. Using animal models, periconceptional 
exposure to nonabsorbable ATB was shown to induce variations in GM composition 
in offspring associated to reduction in social interactions and increased anxiety 
[29]. Other drugs lead to similar observations. In mice, modeling maternal exposure 
to valproic acid, an antiepileptic drug induced lasting changes in the offspring GM 
composition, which was associated with neuroinflammation, abnormal GI physiol-
ogy, and ASD-like behavioral abnormalities [30]. All these observations point to 
the common hypothesis that early exposure to drugs can modify GM composition 
transiently or permanently, possibly affecting the severity of non-GI-related 
symptoms of ASD patients.
Apart from exposition to drugs, another emerging explanation for the differ-
ence in GM between ASD and healthy individuals is immunological. Maternal 
infection during pregnancy was shown to alter microbial composition and is a 
primary environmental risk factor for ASD [31]. GM alterations (especially in the 
bacterial classes clostridia and bacteroidia) and higher gut permeability are seen in 
a maternal immune activation model of ASD [18]. Male progenies of pregnant mice 
injected during pregnancy with a viral mimetic develop abnormal communication 
and sociability, repetitive behaviors, and increased anxiety. Another well-estab-
lished brain-gut connection is the role of stress and its mediators in altering the 
GM. Maternal separation is a typical model of early-life stress employed in animal 
studies. In rats, early maternal separation does not only lead to a dysbiotic state of 
the GM that persists into adulthood but also results in functional GI symptoms and 
long-term cognitive and behavioral deficits [32]. Likewise, psychological stress was 
shown to alter colonic mucosa-associated microbiota, with significant decrease in 
abundance of health-benefit bacteria, such as Lactobacillus, while abundance of 
clostridia increased [33]. Although one cannot extrapolate from mice to human 
without further evidence, these findings nonetheless suggest that the differences 
seen in the GM of ASD patients may be a result of immunological changes.
Further, metals and other contaminants have also been identified to increase 
the risk for ASD knowing their capacity to interfere with the composition and 
metabolic activity of the GM. In fact, results of a study evaluating the interaction 
between environmental chemicals and GI microorganisms suggest that alterations 
in the levels of seven elements (Pb, As, Cu, Zn, Mg, Ca, and Hg) and nine genera 
of GM (Bacteroides, Parabacteroides, Sutterella, Lachnospira, Bacillus, Bilophila, 
Lactococcus, Lachnobacterium, and Oscillospira) may be related to ASD [34]. 
Excessive accumulation of these typical neurotoxic elements leads to abnormally 
increased abundance of several genera and is reported to be closely related to poorer 
intellectual function [35].
Taken together, ASD is thought to be a result of a combination of different 
interacting mechanisms that each contributes a fraction of disease risk.
2.3 Microbial and metabolic dysregulations in autism spectrum disorder
Previously, much research effort on ASD focused on genetic, neurological, 
and behavioral aspects of disease. Recently, the evidence of the impact of dysbio-
sis on CNS raised interest in the analysis of the potential link between GM and 
ASD. So far, various studies demonstrated that children with ASD exhibit different 
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compositions of GM compared to healthy controls [36–43]. Moreover, exciting 
work with animal models widely deepened the possible role of gut microorgan-
isms in the pathogenesis of such disorders [44, 45]. These evidences have led to the 
hypothesis that GM alteration is not only associated with ASD but may play a key 
role in the exacerbation of ASD symptoms and/or its pathogenesis, at least for some 
ASD subgroups [14]. Overall, most studies agree that GM composition is distinctive 
in ASD compared to healthy controls, but results are often inconsistent as to the 
nature and/or extent of GI bacterial community differences, failing to generate a 
coherent picture. Microbiota analyses reported tenfold higher counts of pathogenic 
Clostridium spp. in children with ASD compared with healthy controls [46, 47]. 
Clostridium is known to produce neurotoxins and P-cresol, cause higher propionic 
acid levels, and promote conditions that favor inflammation and exacerbate ASD 
symptoms. On the other hand, there have been some consistent findings of decrease 
in certain beneficial bacteria, specifically Bifidobacterium [40, 48, 49] known for 
its health-benefit properties. Then, the composition of GM of ASD individuals 
has been characterized, showing a reduction of the Bacteroidetes/Firmicutes ratio 
which pointed to elevated numbers of Firmicutes in contrast to decreased levels of 
Bacteroidetes [36, 39, 41, 49–51]. Bacteroidetes are short-chain fatty acids (SCFA) 
producing bacteria, and their metabolites, especially propionic acid, may influence 
the CNS and autism behavior by modulating the GBA [36]. Moreover, species of 
Desulfovibrio were also isolated from the stool of patients with ASD, and, to a lesser 
extent, in non-affected siblings [52]. Desulfovibrio could be an important contribu-
tor to GI inflammation, as its major metabolic by-product—hydrogen sulfide—is 
cytotoxic to colonic epithelial cells. Furthermore, the presence of autistic symptoms 
in children with ASD has been correlated with a less diverse gut microbiome, with 
less carbohydrate degrading and fermenting bacteria of the genera Prevotella, 
Coprococcus, and the unclassified Veillonellaceae in ASD microflora samples as 
compared to the healthy controls [39]. This decrease in GM diversity can lead to a 
loss of key signals required for normal brain maturation. Additionally, increased 
Sutterella were found in significant numbers in intestinal biopsies and stools of 
ASD children [48, 50]. This genus is known to regulate mucosal metabolism and 
intestinal epithelial integrity. Lastly, there were still some conflicting results 
about the alterations of Akkermansia, Ruminococcus, and Faecalibacterium in ASD 
patients. Akkermansia and Ruminococcus are mucin-degrading bacteria [40], and 
Faecalibacterium is regarded as commensal or even beneficial due to its function of 
producing anti-inflammation butyrate [45].
Thus, the existence of a GI dysbiosis as an actor in the ASD etiopathogenesis 
remains a controversial topic. Indeed, other studies comparing children with ASD 
and their healthy siblings reported no meaningful difference in GM composition 
[53, 54]. According to the authors, other explanations for the GI dysfunction in 
this population should be considered, including elevated levels of anxiety and 
self-restricted diets. Therefore, given the higher incidence of ATB usage and often 
different diets compared with neurotypical individuals, both of which can alter the 
composition of the GM, such data should be interpreted with care.
Dysbiosis in ASD involves not only bacterial species but also yeasts, as reported 
in recent studies [40, 41, 55, 56]. One culture-based study showed significant pres-
ence of Candida species in the feces of children with ASD, mainly Candida albicans. 
It also identified hyphae formation, suggesting that the dimorphic yeast had 
switched to its invasive and adhesive form. However, another study did not report 
such overrepresentation of Candida in ASD children compared to control ones [49].
Moreover, correlations between ASD and GI disturbances may not alone be driven 
by the composition of the GM but also by differences in its functionality, such as the 
bacterial metabolites that could play a role in the GBA. Indeed, overproduction of 
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bacterial metabolites (e.g., p-cresol) and SCFA (e.g., propionic acid) is frequently 
described in infants with ASD [30, 49, 57]. These compounds induce intracellular 
signaling and modulate host gene expression related to neurotransmission systems and 
behavior [58]. P-cresol seems to negatively affect the homeostasis of colonic epithelial 
cells in children with ASD.  When tested in vitro, excessive concentration of p-cresol 
showed deleterious metabolic and genotoxic effects on colonocytes [59]. In addition, 
early exposure to p-cresol may contribute to the severity of behavioral symptoms and 
cognitive impairment in ASD toddlers. On the other hand, propionic acid is known to 
have a number of direct effects on gut physiology. It increases the contraction of colonic 
smooth muscle, dilates colonic arteries, stimulates serotonin release, and decreases gas-
tric motility, which could be easily related to the GI abnormalities frequently observed 
in many ASD patients [60]. In fact, lower plasmatic levels of propionic acid have been 
reported in ASD children as an aspect of metabolic alteration in gut host-microbial 
co-metabolism. Authors related the occurrence of lower propionic acid in the plasma 
to elevated levels of propionic acid in the brain [61]. Additionally, administration of 
neurotoxic dose of propionic acid to animals was effective in inducing autistic features. 
Orally dispensed propionic acid was reported to induce oxidative stress. Elevated inter-
leukin 6 (IL-6), tumor necrosis factor α (TNF-α), and interferon γ (INF-γ) confirmed 
the neuroinflammatory effect of propionic acid [61]. When propionic acid was injected 
into the cerebral ventricles of rats, the rats showed biologic, chemical, and pathologic 
changes that are characteristic of ASD [62]. These chemicals can also alter the intercel-
lular spaces between the cells, resulting in the “leaky gut syndrome” that can lead to 
detrimental neurologic effects.
Dysbiosis can also affect the functional intestinal barrier that can lead to an 
alteration in the intestinal permeability referred to as “leaky gut” state, a funda-
mental factor underlying the relationships between ASD and the GM [63]. Indeed, 
several reports show increased gut permeability in ASD patients [64]. Disrupted 
barrier function facilitates the translocation of bacterial metabolites from the gut 
into the bloodstream to possibly reach the otherwise sterile CNS inducing directly 
inflammatory reactions. One important bacterial component is the lipopolysaccha-
ride (LPS) that was shown to increase the activity of areas deputed to the emotion-
alism control such as amygdale [65]. It also leads to the production of inflammatory 
cytokines that critically alter the physiological brain activity, modulating the neuro-
peptides synthesis [66]. Moreover, it has been demonstrated that the administration 
of low doses of LPS in healthy subject is associated to increased pro-inflammatory 
cytokines and plasma norepinephrine, with higher depression rates, fatigue, and 
apathy [67]. Consistent with this, a study showed LPS serum levels were signifi-
cantly higher in autistic patients compared to heath individuals and correlated with 
socialization scores in an inverse and independent manner [68].
3.  Restoring the gut ecosystem: therapeutic outlooks for autism 
spectrum disorder
Despite increased ASD diagnoses, there remains no US Food and Drug 
Administration (FDA)-approved pharmaceutical treatment to alleviate core symp-
toms of ASD [69]. Currently, recommended management strategies essentially 
involve rehabilitation, educational interventions, speech therapies, psychiatric 
medications, and specific treatments for individual comorbidities [70], all with lim-
ited success [71]. Considered the emerging role of gut dysbiosis in ASD, interest in 
rebalancing human GM as a possible therapeutic approach is growing [72]. Indeed, 
targeting the GM in children with ASD through administration of ATBs, pro- and 
prebiotics, and nutritional approaches or, more recently, through fecal microbiota 
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transplantation (FMT) has been shown to improve not only GI disturbances but 
also behavioral and neurophysiological abnormalities associated with ASD [18, 24].
3.1 Antibiotics/antifungals
ATB therapy is used for the management of ASD and is routinely prescribed to 
treat ASD symptoms associated with several underlying disorders like pediatric 
autoimmune neuropsychiatric disorder associated with streptococcal infections 
(PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS) [72]. 
Short-term administration of vancomycin was shown to provide significant 
improvement in both GI and behavioral disturbances in a subset of children with 
ASD [73]. Unfortunately, this attempt had only partial success since children 
relapsed, and benefits waned upon treatment termination. As vancomycin is 
a poorly absorbed ATB known to destroy Gram-positive anaerobes, observed 
improvement is believed to be the consequence of temporary elimination of toxin-
producing clostridia population. Hence, symptomatic relapse was attributed to the 
spore-forming capacity of these bacteria, and spores resistant to ATB would later 
germinate into vegetative forms once treatment has stopped [46].
Children with ASD, particularly those with GI disease, are sometimes treated 
with antifungal agents, as they may have increased incidence of fungal infection. 
Despite the lack of evidence of fungal overgrowth in children with ASD, parents 
find that antifungal therapies can often be beneficial and may be a useful adjuvant 
for the treatments of ASD [74].
Thus, it is possible to speculate that anti-infectives, through modulation of GM, 
should be able to influence symptoms and expression of psychiatric disorders. 
However, ATB resistance (and to some extent antifungal resistance) is a major public 
health concern, making the safety of ATB/antifungal treatments ethically problem-
atic, if they do prove to be beneficial. Therefore, extensive and prolonged use of 
ATB/antifungal treatments may not be advisable as a long-term therapy for ASD.
3.2 Probiotics
One of the most nutritional popular approaches selectively modulating the GM 
is probiotic supplementation due to ease of use, wide availability, and good safety 
profile. Probiotics are defined as live microorganisms that when administered in 
adequate amounts confer a health benefit to the host [75]. The main species used are 
one Escherichia coli strain, several lactic acid-producing Lactobacillus, a number of 
bifidobacterial strains, and a yeast Saccharomyces boulardii. Research on probiotics 
has shown efficacy in prevention or treatment of a wide variety of diseases associ-
ated with GI difficulties. Recently, some evidence has been accumulated regarding 
the possible role of probiotics in modulating symptoms of certain psychological 
diseases such as depression and anxiety as well as ASD [76–78]. Hence, a new class 
of probiotics, termed as psychobiotics, has emerged and refers to living organisms 
with beneficial effects on mental health [79]. In spite of the well-documented 
beneficial effects of probiotics, testing for ASD is still in its infancy, and the exact 
mechanism of their action has not been thoroughly elucidated to date, though there 
are several hypotheses. Implicating correction of both composition and/or activities 
of GM is the first mechanism of action of probiotics through several mechanisms 
including bacteriocins and metabolites, such as lactic, propionic, and acetic acids.
Hence, because ASD patients present GI dysbiosis, which may exacerbate the 
disease, these patients could benefit from GM modulation through probiotic supple-
mentation. Conversely, other investigations have shown that probiotic administra-
tion could act independently from GM alterations by inducing a stabilization of the 
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microbial communities making them less susceptible to perturbations from stressors 
such as ATBs, poor diet, and psychological stress [80]. Moreover, probiotics may cor-
rect the imbalance in the activity of the GM without changing its composition, via 
their metabolites released in the gut lumen or by potentially correcting the overpro-
duction of harmful and underproduction of beneficial gut bacterial products [81]. 
The increased intestinal permeability in ASD may also be ameliorated by probiotics 
which are able to enhance the mucosal barrier. This supports the concept that probi-
otics can provide protective effect by preventing the metabolites of exogenous toxic 
substances from leaving the gut and entering the bloodstream to affect the brain 
[70]. Probiotics may therefore maintain or improve gut barrier integrity and aid in 
ASD rehabilitation by promoting “leaky gut” healing. Lastly, given the multiple find-
ings of aberrant immune activation and higher levels of gut inflammation in a subset 
of individuals with ASD, that a major part of the immune system is concentrated in/
around the intestinal mucosa, and that the GM plays an important role in the matu-
ration and the regulation of the immune response, another mechanism of action of 
probiotics may be on the immune system [82]. Probiotics can downregulate gut and 
CNS inflammatory pathways in a species- and strain-specific manner [83], by pro-
moting the production of regulatory T cells, diminishing the levels of LPS, providing 
tolerogenic signals, and boosting the brain-derived neurotrophic factor (BDNF). 
BDNF is a protein that promotes the survival of existent neurons in the developing 
brain, fosters the growth and differentiation of new neurons, and regulates the 
formation and plasticity of synaptic connections, thereby playing an essential role 
in the normal neurological development [6]. Impairment in BDNF signaling in early 
developmental phases is thought to be related to CNS abnormalities, the most severe 
forms of ASD, as well as intellectual disability [84]. Probiotics have been shown also 
to modulate the intestinal immune system by the production of secreted factors and 
metabolites that affect growth and function of intestinal epithelial and immune cells 
[85]. Moreover, probiotic immunomodulation may occur through inhibiting the pro-
duction of pro-inflammatory cytokines such as IL-12, TNF-α, and INF-α or increase 
the expression of anti-inflammatory mediators such as IL-10 and transforming 
growth factor beta (β-TFGF). Thus, by alleviating gut inflammation and suppressing 
dysregulated immune functions, probiotic supplementation may be effective for 
improving both gut microbial and behavioral problems in ASD. Lastly, probiotics 
could act via the vagus nerve-mediated GBA to influence neurotransmission and 
mood states [86]. They can exert central actions by influencing several neuroactive 
metabolites such as gamma-aminobutyric acid (GABA) and serotonin which are also 
associated with neuropsychiatric disorders [87, 88]. Consequently, administration of 
probiotics regulates the behavior in a way that significantly reduces anxiety, depres-
sion, and stress and promotes positive emotional changes. Therefore, probiotic 
administration might be a useful new therapeutic option to restore normal GM, 
reduce inflammation, restore epithelial barrier function, and possibly improve some 
behavioral symptoms associated with ASD.
A role for probiotics has been suggested for children with ASD as well, as 
preliminary findings from experimental animals studies provide some evidence that 
administration of selected probiotics may be effective in reducing neurologic signs 
and symptoms associated with gut dysbiosis. In a summary of studies to date, sev-
eral probiotic strains, i.e., Bifidobacterium sp. (B. longum, B. breve, B. infantis, and B. 
bifidum), Lactobacillus sp. (L. acidophilus, L. helveticus, L. rhamnosus, L. plantarum, 
L. sporogenes, L. bulgaricus, L. delbrueckii, L. salivarius, L. casei, and L. paracasei), 
Streptococcus sp. (S. thermophilus and S. salivarius), and Bacteroides fragilis, are 
presumed to be effective in ameliorating CNS functions related to mental disorders, 
as shown through several animal models [18, 89–92]. In a mouse model of ASD 
induced by maternal immune activation, oral administration of human commensal 
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B. fragilis corrected intestinal permeability, restored GM, improved GI physiology, 
and abolished ASD-like behavioral disruptions [18]. Interestingly, the probiotic also 
corrected altered expression of the tight junction proteins in the colon and restored 
the increase in the pro-inflammatory cytokine IL-6. Moreover, B. fragilis treat-
ment mitigated elevations in several maternal immune activation-induced serum 
metabolites associated with ASD. One metabolite of particular interest was 4-ethyl-
phenylsulfate (4EPS) which is chemically similar to p-cresol and is thought to be a 
possible putative urinary biomarker for ASD [59]. Hence, the administration of B. 
fragilis in a mouse model for ASD was able to reverse autistic symptoms and meta-
bolic derangement. Similarly, reconstituting GM with a human breast milk and gut 
commensal Lactobacillus reuteri completely corrected social deficits and reversed 
aberrant neurotransmission in maternal high-fat diet offspring [89]. This is intrigu-
ing in light of reports that risperidone, an FDA-approved treatment for ASD, does 
not correct social abnormalities [93]. Treatment with L. reuteri resulted also in 
reduction of stress-induced corticosterone, and stimulation of the production of 
oxytocin, a key regulator of social behaviors, involved in the mesolimbic dopamine 
reward system, which is thought to be dysregulated in ASD [94]. On another hand, 
a recent study performed on hamsters in which autistic-like behaviors were induced 
by propionic acid and clindamycin administration studied the therapeutic effect 
of a 3-week oral treatment with a mixture of bifidobacteria and lactobacilli strains 
(Protexin®) [91]. Protexin® administration was effective in rebalancing GM, ame-
liorating oxidative stress, and counteracting behavioral deficits. Finally, in maternal 
separation-induced early-life stress mice model, oral administration of L. plantarum 
as a psychobiotic strain significantly reduced anxiety while improving locomotor 
activities and exploratory behavior [92]. According to various animal studies, L. 
plantarum can modulate the levels of neurotransmitters in the brain by influencing 
gene expression in the CNS and increasing dopamine level in the prefrontal cortex 
[92]. Summing up, by conducting behavioral tests in animal models, research 
provided convincing evidence for the efficacy of psychobiotic strains in improving 
ASD-like behaviors. However, the experimental evidence for the positive behavioral 
changes observed in animal models after administration of probiotics raises the 
interesting question whether the same result also applies to humans.
To date only few studies explored the effects of probiotics on ASD clinical 
features in humans. Table 1 synthesizes available evidence on the efficacy and 
safety of probiotic supplementation as an adjunctive treatment for ASD [49, 51, 
73, 95–106]. In these studies, probiotic interventions varied across all of the tri-
als. Concentrations of the probiotic strains administered ranged from 107 to 1010 
colony-forming units (CFU)/dose, and their usage by recipients differed. Strains 
were administered alone or as mixed strains with or without other additives (immu-
nomodulators [99] and ATBs [73]). In summary, despite the variability in species, 
strains, dosages, and duration utilized, all studies pointed toward a similar trend 
of improvement in both caregiver-reported ASD and GI symptoms after probiotic 
therapies. Accordingly, a recent survey found that almost 20% of physicians treat-
ing ASD patients encourage probiotic use, and almost 60% accept their use [107]. 
In a recent study, the positive effect of probiotic treatment was represented not only 
by the ability to consistently normalize the Bacteroidetes/Firmicutes ratio and restore 
the amounts of Desulfovibrio and Bifidobacterium in children with ASD [51] but 
also by the tendency to reduce intestinal inflammation and permeability. Similarly, 
another study associated changes in the GM composition to improvements in GI 
symptoms and functioning [102]. After probiotic supplementation in the latter 
study, children with ASD experienced a significant increase in Bifidobacterium 
and Lactobacillus in their fecal stool samples with a simultaneous reduction of 
Clostridium species. Furthermore, in a third study, probiotic feeding of children 
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Authors Study design Diagnosis Probiotic therapy
Blades M., 2000, 
UK [95]
Case report of a 6 y with 
ASD
Not reported Strain and dosage not provided 
Administration for 2 mo
Sandler et al., 
2000, USA [73]
Open-label with self-
control study
11 ASD subjects
(10 M, 3.5–7 y)
CARS L. acidophilus, L. bulgaricus, and B. 
bifidum, 40 × 109 CFU/mL
QD for 4 wk
Parracho et al., 
2010, UK [96]
Randomized, double-
blind, PBO-controlled, 
cross overdesigned 
feeding study
17 ASD subjects
(14 M, 4–16 y)
Not reported L. plantarum WCFS1
4.5 × 1010 CFU
QD for 3 wk
Ray et al., 2010, 
USA [97]
Open-label with self-
control study
10 ASD subjects
(Gender not reported, 
4–15 y)
ATEC L. rhamnosus, B. bifidum, L. acidophilus, 
B. infantis, B. longum, S. thermophilus, 
L. plantarum, L. salivarius, L. reuteri, L. 
casei, L. bulgaricus, L. acidophilus DDS-1, 
and L. sporogenes
Dosage not provided
BID for 21 d
Adams et al., 
2011 USA [49]
Retrospective case 
cohort study
57 ASD subjects:
19 PS vs. 38 no PS
(50 M, 3–9 y)
ATEC Strain and dosage not provided
QD
Kałzuna-
Czaplinska et al., 
2012, Poland [98]
Open-label with self-
control study
22 ASD subjects
(20 M, 4–10 y)
DSM-IV L. acidophilus (strain Rosell-11)
5 × 109 CFU/g
BID for 2 mo
West et al., 2013, 
USA [99]
Open-label with self-
control study
33 ASD subjects
(Gender not reported, 
3–16 y)
Not reported L. acidophilus, L. casei, L. delbrueckii, B. 
longum, and B. bifidum
1 × 1010 CFU/capsule
One capsule TID for 6 mo
Partty et al., 
2015, Finland 
[100]
Randomized, double-
blind, PBO-controlled 
prospective follow-up 
study 75 ASD subjects
40 PS (24 M, 13 y) vs. 
35 PBO
(16 M, 13 y)
ICD-10 L. rhamnosus GG
1 × 1010 CFU
QD for 6 mo
Tomova et al., 
2015, Slovakia 
[51]
Case control cohort 
study
10 ASD subjects (9 M, 
2–9 y)
9 non-ASD siblings 
(7 M, 5–17 y)
10 non-ASD controls 
(10 M; 2–11 y)
ICD-10 3 strains of Lactobacillus (60%, one is 
L. casei), 2 strains of Bifidobacterium 
(25%, one is B. longum), and 1 strain 
of Streptococcus (15%, exact strain 
information not provided)
Dosage not provided
One capsule TID for 4 mo
Grossi et al., 
2016, Italy [101]
Case report of a 12 y boy 
with ASD
DSM-V + ADOS-2 B. breve, B. longum, B. infantis, L. 
acidophilus, L. plantarum, L. paracasei, 
L. bulgaricus, L. delbrueckii, S. 
thermophilus, and S. salivarius
9 × 1010 CFU/g Bifidobacteria
8 × 1010 CFU/g Lactobacilli, and
20 × 1010 CFU/g Streptococci
QD for 4 months
Prebiotics and Probiotics - Potential Benefits in Nutrition and Health
12
with ASD significantly increased levels of the beneficial bacteria, specifically, the 
amount of lactobacilli and enterococci, and reduced their fecal Clostridium counts 
[96]. Additionally, in the same study, the efficacy of probiotic supplementation 
seemed to be age-dependent, with better effects noticed on younger children, 
underscoring the importance of early interventions. Although all aforementioned 
studies showed changes in GM after the implementation diet with probiotics, only 
some of them analyzed the correlations with GI symptoms and reported improve-
ment of GI function indices [96, 98, 101, 102, 105]. In fact, a survey conducted 
on caregivers showed that daily administration of a specific five-strain probiotic 
decreased the severity of comorbid GI problems [99]. Concurrent with increases 
in the proportion of normal stools, there was an increased appetite and willingness 
to consume novel foods that may be due to reduced abdominal pain or improved 
stool evacuation [105]. Besides, in one case study report, a multi-strain mixture 
of 10 probiotics not only relieved the GI disturbances but also improved ASD 
core symptoms [101]. However, benefits reversed after the term of the therapy. In 
addition to the alteration in GI dysfunction and GM, more than half of the stud-
ies also included assessment of change in behavior after probiotic therapy. Most 
of these studies recorded a reduction in the severity of ASD symptoms, although 
not all reached significance. Noted positive effects on mood and general behavior 
were (i) statistically significant differences in behavioral scores for disruptive/
antisocial behavior, anxiety problems, communication disturbances, and self-
absorbed behavior compared to baseline [96, 104]; (ii) decrease in the severity of 
Authors Study design Diagnosis Probiotic therapy
Shaaban et al., 
2017, Egypt 
[102]
Prospective, open-label 
cohort study
30 ASD subjects (19 M, 
5–9 y)
30 age/sex-matched 
non-ASD siblings
DSM-V + ADOS + 
ADI-R
L. acidophilus, L. rhamnosus, and B. 
longum
10 × 107 CFU/g
5 g QD for 3 mo
Liu et al., 2019, 
Taiwan [103]
A double-blind, 
randomized, PBO-
controlled, parallel 
feeding study
71 ASD subjects:
36 PS (36 M, 7–15 y) vs. 
35 PBO
(35 M, 7–15 y)
DSM-V + ADI-R L. plantarum PS128
3 × 1010 CFU/capsule
1 capsule QD for 4 wk
Kobliner et al., 
2019, USA [104]
Case report of a 16 y 
child with ASD
Not reported S. boulardii
3 × 109 CFU/capsule
Week 1: 6 capsules QD. Weekly 
increases reaching a final dose of 12 
capsules BID. After 3 mo, weaning 
down to 3 capsules BID
Sanctuary et al., 
2019, USA [105]
Double-blind, crossover, 
randomized clinical trial
8 ASD subjects
(7 M, 4–11 y)
ADOS B. longum subsp. infantis
2 × 1010 CFU
QD for 5 wk
y, years; M, male; PBO, placebo; PS, probiotic supplementation; ADI-R, Autism Diagnostic Interview-Revised; 
ADOS, Autism Diagnostic Observation Schedule; ATEC, Autism Treatment Evaluation Checklist; CARS, Childhood 
Autism Rating Scale; DSM-IV, Diagnostic and Statistical Manual-4th Edition; ICD-10, International Classification 
of Diseases-10th Edition; d, days; wk, weeks; mo, months; CFU, colony-forming unit; g, gram; QD, once a day; BID, 
two times a day; TID, three times a day; QID, four times a day.
Table 1. 
Main clinical trials investigating the effectiveness of probiotic supplementation in autism spectrum disorders.
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speech/language/communication performance [97, 101]; (iii) progress in sociabil-
ity, sensory and cognitive awareness, physical health, and behavior [99, 102]; and 
(iv) changes in adaptive, repetitive, and aberrant behaviors including irritability, 
lethargy, stereotypy, and hyperactivity [105]. Conversely, in other investigations, 
no statistically significant differences in behavioral scores were detected between 
probiotics and placebo control groups [73, 103]. Lastly, probiotic treatment reversed 
the metabolic disruptions and improved behavioral performance. In one of the 
studies, probiotics significantly lowered the concentration of myeloperoxidase (a 
marker of inflammation and oxidation) in ASD patients compared to other autistic 
individuals not taking probiotics [106]. Metabolic changes were also observed in 
another former study in which probiotics substantially diminished fecal levels of 
propionic acid in ASD individuals [49]. In a third study, probiotic supplementation 
significantly reduced metabolic products of the pathogenic Candida yeast species 
[98], which are remarkably elevated in the urines of individuals with ASD [108]. 
This biological improvement also corresponded to behavioral outcomes, where 
children showed significant ameliorations in their ability to concentrate and fulfill 
orders. In 2015, an intriguing randomized trial demonstrated that early postnatal 
probiotic administration has a preventive effect on ASD and may reduce the risk 
of developing further neuropsychiatric disorder [100]. Results showed that from 
children randomly assigned to probiotic or placebo groups during the first 6 months 
of life, 17% in the placebo group had a diagnosis of ASD at the age of 13, while none 
of the children in the probiotic group did.
At last, though probiotics are considered a relatively risk-free option for individu-
als with ASD, the current literature cannot confidently state their safety as there is a 
paucity of systematic reporting of adverse events. However, among the studies that 
monitored side effects, the reported ones (bloating, skin rash, worsening constipation 
or diarrhea, and weight loss) appear to be mild, transient, and infrequent [96, 99, 
102, 105]. Conclusively, due to the large heterogeneity between trials, studies provide 
only suggestive but not conclusive evidence regarding the efficacy of probiotics on GI 
and behavioral symptoms among ASD patients. Thus, future probiotic research holds 
hopes for discovering the optimal species, strains, strength, and length of probiotic 
therapy for the particular comorbidity profile of different individuals with ASD.
3.3 Prebiotics
The International Scientific Association for Probiotics and Prebiotics (ISAPP) 
defines prebiotics as substrates “selectively utilized by host microorganisms, confer-
ring a health benefit” [75]. Such benefits are not limited to gut homeostasis but can 
extend elsewhere in the organism, leading to improvements of the immune, meta-
bolic, endocrine, or nervous functions. Fructans, comprising fructooligosaccharides 
(FOS) and inulin, and galactans (galactooligosaccharides (GOS)) are the most rec-
ognized prebiotics. Differently from most dietary fibers, which promote growth of a 
wide variety of microorganisms, prebiotics display a selective effect, being a sub-
strate for beneficial strains only, while excluding metabolism by pathogenic bacteria 
[6]. Thus, the main reason for a potential influence of prebiotics on the treatment of 
ASD concerns the selective enrichment of Lactobacillus and/or Bifidobacterium spp. 
Besides, various other mechanisms have been identified through which prebiotics 
can act, including generation of SCFA that have an influence on gut energy metabo-
lism, barrier function, water fluxes, motility [109], elongation of microvilli, increase 
in mucus layer thickness, and consequent protection of gut epithelium. However, as 
with probiotics, prebiotic studies regarding their impact in neurological problems 
are few and not conclusive. In rats, oral administration of GOS elevates BDNF levels 
[110], normalizes LPS-induced anxiety, and modulates cortical IL-1β levels [111], 
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thus confirming the potential role for prebiotics in ASD where anxiety and neuroin-
flammation are prominent clinical features. Lastly, only two clinical trials examined 
the use of prebiotics in children with ASD [105, 112]. In the first study, GOS alone 
did not have a significant effect on GI symptoms, while when combined with bovine 
colostrum, GI symptoms improved as well as irritability scores and stereotypy [105]. 
Similarly, in the second trial, GOS intervention did not show a significant impact 
when provided alone. Nevertheless, when associating GOS treatment with an exclu-
sion diet, notable increases occurred in beneficial bacteria supporting improvement 
in antisocial behavior [112]. GOS also affected SCFA production decreasing propi-
onic acid as a result of normalized GM composition. Thus, it is sensible to postulate 
that combined intervention therapies might have a better impact on ASD individuals 
than single dietary approach and prebiotics could be a useful option for ASD chil-
dren treatment in early life.
3.4 Fecal microbiota transplantation
The process of FMT consists in the delivery of feces from a healthy donor to a 
patient with gut dysbiosis, with the aim of replacing an impaired microbiota with a 
healthy one. Unlike probiotics, where only a restricted number of bacterial species are 
supplemented, FMT allows the transplantation of thousands of different components 
of the healthy GM. In fact, FMT is one of the most effective techniques recently con-
sidered in treating recurrent ATB-refractory Clostridium difficile infection [113] and 
has shown varying levels of success in patients with other GI diseases such as irritable 
bower syndrome [114], and non-GI diseases like autoimmune disorders, obesity, and 
insulin sensitivity [115]. Given the growing evidence for a role of GM disruption and 
GI symptoms in ASD, clinical trials are under way using FMT to treat children with 
ASD. In a recent open-label study, ASD children with chronic GI problems underwent 
a modified FMT protocol, termed microbiota transfer therapy (MTT), consisting of a 
2-week vancomycin treatment followed by bowel cleansing, and administration of a 
high dose of standardized human gut microbiota [24]. After this 10-week treatment, 
MTT induced an 80% improvement of GI function and a slow but steady improvement 
in behavioral ASD scoring, both of them maintained at least 8 weeks after treatment 
stopped. In line with previous reports, few adverse events were described, and the 
most commonly reported include mild diarrhea, abdominal tenderness, flatulence, 
and nausea thus confirming treatment safety and tolerability in autistic patients. 
Coincident with these clinical improvements, FMT confirmed its ability in modifying 
GM composition by significantly increasing bacterial diversity and the relative abun-
dance of Bifidobacterium and Prevotella [24]. Two years after this original clinical trial 
was completed, re-evaluation of the participants showed that GI benefits were mostly 
maintained and ASD symptoms were reported to have improved significantly since 
the end of treatment [116]. Changes in the GM also persisted for 2 years. According 
to these encouraging observations, intensive FMT intervention can be considered an 
effective and well-tolerated promising approach in treating children with ASD who 
have GI problems. However, the safety of FMT should be considered as it carries many 
risks including aspiration and transmission of opportunistic pathogens to recipients. 
Therefore, major efforts at refinement are necessary before FMT can be adopted widely.
3.5 Dietary interventions
A number of nutrition intervention strategies have been explored to treat 
behavioral symptoms and comorbid GI distress [117], but evidence is still relatively 
weak and sometimes inconsistent, as in the case with gluten-free and/or casein-free 
(GF/CF) diet and ketogenic diet (KD).
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Various observational studies reported alleviation of GI problems and/or 
significant behavioral improvements in ASD children following an extended GF/CF 
diet [118, 119]. However, elimination diets for ASD patients should not be recom-
mended as standard treatment and only be considered after reaching a diagnosis of 
an adverse food reaction since dietary restrictions are likely to limit variety of food 
intake and provoke nutritional deficiencies in developing children [120]. Moreover, 
GF/CF diet can also exacerbate the already disrupted gut microbial composition in 
ASD by reducing beneficial and increasing opportunistic bacteria [121].
Improvements in neurobehavioral symptoms have also been reported in ASD 
as a result of following a KD. KD is a high-fat and low-carbohydrate diet that, due 
to its beneficial effects on GM composition, has been suggested as a treatment for 
ASD. In humans, administration of KD to individuals with ASD results in increased 
sociability, improved communication, and decreased repetitive comportments 
[122]. In animal models, both improvement of behavioral symptoms and com-
positional remodeling of GM after KD have been described [123, 124]. However, 
KD causes an “antimicrobial”-like effect by significantly decreasing the total gut 
microbial abundance. Moreover, it results in an increase in clostridia species and 
may lead to adverse effects such as dehydration [125]. So, side effects and increase 
in harmful bacteria in the GM associated with limited number of positive results 
constitute insufficient evidence for the practicability of KD as a treatment for ASD.
4. Conclusion and perspectives
In the last few years, the importance of GM in the maintenance of physiologi-
cal state into the CNS is supported by several studies that have shown qualitative 
and quantitative alterations of the intestinal flora in a number of neuropsychiatric 
diseases. Within neurobehavioral disorders, it seems that at least a subset of the 
cases comprising ASD are connected to, and perhaps dependent on, the health 
and well-being of the GM. In recent years the increased prevalence of ASD, along 
with the evidence of a significant link between ASD and GI disturbances, raised a 
special interest in exploring the reciprocal influences between GM and brain under 
the so-called GBA. Alterations of GM composition in children with ASD presented 
in the literature mainly consist in reduced levels of Bifidobacterium and increased 
levels of Clostridium spp. and Desulfovibrio. However, the available data do not allow 
to define a characteristic and unique profile of ASD. If dysbiosis is confirmed to be 
a precipitating factor in ASD, then several potential therapeutic approaches ranging 
from ATBs, probiotics, prebiotics, up to FMT and other nutritional strategies may 
be useful adjuvant treatments in these patients. Future research, together with the 
application of state-of-the-art “omics” methods, could address possible unequivo-
cal microbial biomarkers for ASD. Further, as dysbiosis contributes to a significant 
subset of ASD, specific identification of ASD endophenotypes will allow patient 
stratification and personalized interventions. Addressing microbial processes could 
be the aim of the next pharmacological therapy of ASD that will potentially help to 
alleviate the burden of this disorder for the millions of people affected worldwide.
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